Sponsored

Imugene’s (ASX:IMU) HERIZON study results to feature at ESMO Asia Congress - Kalkine Media

October 07, 2022 02:37 PM AEDT | By Manisha
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Imugene Limited will be giving an oral presentation of an abstract about the overall survival results from its HER-Vaxx HERIZON study at the ESMO Asia Congress 2022
  • The event will be held from 2-4 December in Singapore
  • Principal investigator Marina Maglakelidze will present the abstract during a session on gastrointestinal tumours on 4 December 2022, 1:40pm (SGT)

Imugene Limited (ASX:IMU), a renowned clinical-stage immuno-oncology company, has got a major opportunity to present an abstract about the overall survival results from its HER-Vaxx HERIZON study at the ESMO Asia Congress 2022.

The ESMO Asia Congress has accepted the company’s abstract for an oral presentation at the event, scheduled to be held from 2-4 December in Singapore. At the annual meet, cancer professionals from Asia and other parts of the world come together to present and discuss the most recent scientific and clinical developments in the field of oncology.

The title for the oral presentation and abstract (no. 74MO) is 'HERIZON Overall Survival Results: A Study of IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing Metastatic or Advanced Gastric/GEJ Cancer'. The presentation will be a part of a session to be conducted on gastrointestinal tumours on 4 December 2022, 1:40pm (SGT), by principal investigator Marina Maglakelidze.

An overview of HERIZON study

The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer immunotherapy, developed for treating tumours which overexpress the HER-2/neu receptor, like lung, gastric, breast, pancreatic, and ovarian cancers. The immunotherapy is built using multiple B cell epitopes derived from the extracellular domain of HER2/neu.

Imugene’s shares were spotted trading 3.947% higher at AU$0.197 (as at 02:42 PM AEDT) on 7 October 2022.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.